Kornimate/medical-research-clean huggingface dataset:
effect of herbal formulation on thrombocytes count

Conditions: Thrombocytopenia

Summary: effect of herbal formulation karika syrup on thrombocyte count.

in this study, we will evaluate the effect of herbal formulation karika (composed of carica papaya leaf extract and tinosporacordifolia) on complete blood count, specifically on platelet count. low platelet count is highly observant during multiple diseases namely dengue, malaria, typhoid, chikungunya, viral infections, and other diseases. the proposed study is a randomized, open, prospective, multicenter clinical trial. extracts found in karika syrup are beneficial in escalating platelet count, and also have anti-inflammatory and antipyretic activity. the therapeutic indication of karika is proven through this clinical study in patients with low platelet count associated with dengue, typhoid, malaria, viral fever, and chikungunya fever. dengue is a tropical disease caused by the rna virus which resides in mosquitoes. symptoms include high-grade fever, visual disturbances, pain in the eyes and head, nausea, vomiting, musculoskeletal pain, stiffness of joints, mild to moderate and severe bleeding, and sometimes puerperal rash appearing on the skin due to a deficiency of thrombocytes. the chikungunya virus is spread by the bite of an infected mosquito. typhoid is caused by salmonella typhi a bacterium. typhoid fever symptoms are seen widely in the human body that may observe from relatively minor cases of diarrhea with low-grade fever to high-grade fever and profound diarrhea with involvement of multiple systems.1

Eligibility criteria:
inclusion criteria: * inclusion criteria: 1. female and male patients of age 14 to 60 years. 2. patient suffering from complaints of weakness, fatigue, puerperal rashes, shortness of breath, low hemoglobin, and history of fever on \& off, epistaxis.18 3. patients from karachi and kapri mori(labors, employed, multigravida females, housewives, domestic helpers, working women, school, college, and university students). 4. all socioeconomic classes are included in the study. 5. patients having a history of covid-19, viral fever, typhoid, and other illnesses in which there has been a low platelet count.2 exclusion criteria: * exclusion criteria: 1. pregnant females are excluded.17 2. patients with co-morbidities like uncontrolled hypertension and liver disorder are excluded.4,5,6 3. patient having known drug reaction from any content of formulation is excluded.7 4. patients suffering from serious illnesses like encephalitis, coma, meningitis, or head injury that make them bedridden or hospitalized are excluded.4,6

Keywords: thrombocyte count, karika
trapeziometacarpal prosthesis vs. resection-interposition arthroplasty

Conditions: Arthropathy of Hand

Summary: rhizarthrosis is a frequently occurring pathology leading to severe limitations in daily life due to pain and loss of function. good clinical results have been reported for some carpometacarpal (cmc) joint prosthesis designs, but high failure rates due to loosening and dislocation must be considered. the study aim was to investigate a new, double mobility cmc-prosthesis design with special focus on (1) the functional outcome and (2) patient quality of life (qol)

the epping resection-suspension arthroplasty procedure was described in 1983 to address the proximal migration of the first ray while providing pain free grip strength without any implants. it has shown rather good functional outcome and pain relief. a reduction in thumb opposition strength of 27% compared to the contralateral side and intermittent pain in physical activity is reported, however. further, studies comparing trapeziectomy and trapeziectomy with tendon interposition recommend trapeziectomy due to the simple technique and comparable outcome. endoprosthesis of the first carpometacarpal (cmc) joint represents a different treatment strategy aiming at an exact reconstruction of the joint geometry. some studies report excellent functional outcome and pain relief. however, there are some prosthesis designs (cemented and uncemented) with high rates of loosening, luxation and poor subjective results. to address these issues, a prosthesis was designed combining a cylindric, double mobility cup and a hydroxyapatite covered stem and cup available in different sizes. the aim of this study was to compare this new prosthesis design to the epping arthroplasty as the current standard in the investigator's institution regarding (1) the functional outcome with special focus on mobility and strength and (2) patient quality of life (qol) and pain relief. note: the registration of this trial on clinicaltrials.gov was carried out retrospectively after primary completion of the study.

Eligibility criteria:
inclusion criteria: * symptomatic rhizarthrosis grade 2 and 3 according to eaton's classification, * failed conservative treatment prior to surgery, * written informed consent to the study. exclusion criteria: * scaphotrapezotrapezoidal (stt) arthrosis, * former cmc joint surgery, * patients under custodianship.
monogenic diabetes misdiagnosed as type 1

Conditions: Diabetes Mellitus, Type 1; Monogenic Diabetes; Neonatal Diabetes; Maturity-onset Diabetes in the Young (MODY); Wolfram Syndrome; Wolcott-Rallison Syndrome; Mitochondrial Diabetes

Summary: the study has two aims: 1. to (1a) determine the frequency of monogenic diabetes misdiagnosed as type 1 diabetes (t1d) and (2) to define an algorithm for case selection. 2. to discover novel genes whose mutations cause monogenic diabetes misdiagnosed as t1d.

aim 1. the investigators will recruit 5,000 cases diagnosed as t1d under the age of 25, from 17 participating clinics across canada. all cases will be tested for four antibodies (against proinsulin, gad65, islet antigen 2 (ia-2), and znt8). cases negative for all four will be exome-sequenced. 1. variant annotation will be focused on known monogenic diabetes genes. variants rated as pathogenic, likely pathogenic or of unknown significance whose zygosity fits the genetic model, will be confirmed in a clinically certified laboratory and communicated to the treating health care team. end-point is the frequency of such variants compared to their frequency in control, non-t1d exomes. 2. the following variables will be examined for the ability to predict monogenic diabetes: negativity for all autoantibodies tested, family history, polygenic t1d risk score, age of onset, sex, glycosylated hemoglobin (hba1c), insulin dose, and presence of syndromic features. predictors will be analyzed by multiple regression and results subjected to jackknife (leave-one-out) validation. machine-learning techniques may be used. aim 2. variants outside known genes in non-diagnostic exomes will be annotated and examined under autosomal dominant, recessive, x-linked and mitochondrial inheritance models. corresponding frequency cutoffs will be 0.0005, 0.01, 0.001 and 0.0005 (if heteroplasmy \>70%). formal mutation-burden analysis will be based on depth-adjusted data from the genome aggregation database (gnomad). genes mutated in more than one unrelated proband will be examined by a statistical approach taking into account the presence of a large number of phenocopies (akawi et al., nat genet. 2015;47:1363-1369). genes that achieve statistical significance will be tested in additional cohorts with international collaborations.

Eligibility criteria:
inclusion criteria: * diagnosis of diabetes under the age of 25 as either type 1 or undetermined type. exclusion criteria: * existing t1d autoantibody testing with a positive result
the think study incidence of neurotrophic keratopathy)

Conditions: Dry Eye

Summary: the study purpose is to evaluate corneal sensitivity in patients that have stage 1 neurotrphic keratopathy (nk). identifying patients with stage 1 nk, may predict those who will in the future require rhngf for optimal visual performance.

the purpose of this study is to evaluate corneal sensitivity in a cross-section of patients with signs of dry eye disease (ded), correlating findings against clinical parameters relating to the severity of disease and impact on quality of vision. identifying those patients with stage 1 neurotrophic keratopathy (nk), i.e. those with corneal staining and reduced sensitivity, may predict those who will in the future require rhngf for optimal visual performance.

Eligibility criteria:
inclusion criteria: \*patients with the following: a diagnosis of dry eye disease central or inferior corneal fluorescein staining defined by the oxford scale reduced tear break up time (tbut) ≤ 10 seconds. * able to comprehend and sign a statement of informed consent. * willing and able to complete all required postoperative visits. exclusion criteria: * ocular surgery (e.g., intraocular, oculoplastic, corneal, or refractive surgical procedure) performed within the last 3 months or at any time in the investigator's clinical judgment if it would interfere with the outcome measures of this study. * evidence of bak or other chemical toxicity that, in the best judgment of the investigator, is causing reduced corneal sensitivity * concomitant use of daily contact lenses that, in the best judgment of the investigator, is causing reduced corneal sensitivity * clinically significant ocular trauma. * active ocular herpes simplex or herpes zoster infection * ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator. * ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye). * active, systemic, or local disease condition that causes clinically significant ocular surface irritation such that it could interfere with the study findings. * moderate to severe (grade 2-4) allergic, vernal or giant papillary conjunctivitis. * severe (grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis) * eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis). * ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity). * participation in this trial in the same patient's fellow eye * patients who are under age 18, pregnant or breastfeeding, or who may become pregnant during participation in the study.
rituximab effect on decreasing glucocorticoid exposition in polymyalgia rheumatica patients experiencing a pmr relapse

Conditions: Polymyalgia Rheumatica

Summary: polymyalgia rheumatica (pmr) is prevalent among elderly. untreated, it leads to major reduction in quality of life. glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing treatment. a proof of concept study on rituximab (rtx) vs placebo showed efficacy in 48 vs 21%(p=0.049) in glucocorticoid free remission after 21 weeks (marsman et al. 2021). though promising, the short study duration, small sample size and only few relapsing patients included in this study require further confirmation. therefore a larger randomised controlled trial with longer follow up will be performed on rtx efficacy on glucocorticoid free remission in relapsing pmr patients during glucocorticoid taper.


Eligibility criteria:
inclusion criteria: * polymyalgia rheumatica (pmr) diagnosis fulfilling the 2012 european league against rheumatism (eular)/american college of rheumatology (acr) classification criteria * experiencing a pmr relapse, defined as recurring of symptoms and increase in erythrocyte sedimentation rate (esr)/ c reactive protein (crp) * unable to reduce glucocorticoid dose below 5mg/day prednisolone or equivalent * informed consent exclusion criteria: * treatment with systemic immunosuppressants (other than gc, mtx, leflunomide and azathioprine) 3 months prior to inclusion; * (clinical) suspect concomitant giant cell arteritis or other rheumatic inflammatory diseases; * concomitant conditions that might significantly interfere with pmr pain or movement evaluation as judged by the investigator; * previous hypersensitivity for rtx or contra-indications to rtx.
genetic biomarkers of child language development in taiwan: an identification and validation study

Conditions: Child Language

Summary: a study of the relation between genetic biomarkers and child language development in taiwan.

the interaction between gene and environment (g×e) can be a very complicated process that influences child development. as a pilot study of child development biomarkers, this study investigates genes related to child language development and language disorder.

Eligibility criteria:
inclusion criteria: * age 2-18 y/o * agree to sign informed consent exclusion criteria: * central nervous system disease * neuromuscular disorders * congenital abnormality * genetic disease * dysesthesia * hearing impairment inclusion criteria of child with language disorder: * patients with language disorder * age 2-18 y/o * agree to sign informed consent * exclusion criteria of child with language disorder: * hearing impairment inclusion criteria of adult: * his or her child participated in this study, and gene abnormality was found.

Keywords: language development gene whole-exome sequencing body function and body structure quality of life
comparison of different functional capacity tests in cystic fibrosis patients with acute pulmonary exacerbation

Conditions: Cystic Fibrosis in Children; Exercise Capacity

Summary: the aim of this study to investigate and compare functional capacity with different tests and to evaluate the relationship between functional capacity and quality of life during acute pulmonary exacerbation in children with cystic fibrosis. exercise tests associated with prognostic values in cf patients and decreased exercise capacity has been correlated with a reduction in health-related quality of life. pulmonary functions, functional capacity and quality of life will examine in this study.

this study will be participated children with cystic fibrosis who will diagnosed acute pulmonary exacerbation. patients' pulmonary function test, functional capacity will be assess and record at hospital admission and hospital discharge and outpatient clinic control. quality of life will be evaluated at only outpatient clinic control . pulmonary function test will be assessed with spirometry, functional capacity will be evaluated with 1-minute sit to stand test and 3-minute step test. and quality of life will be evaluated cystic fibrosis questionnaire-revised (cfq-r).

Eligibility criteria:
inclusion criteria: * childrens with cf diagnosed between 7-18 years of age and hospitalized due to acute pulmonary exacerbation will be included in the study.the diagnosis of acute pulmonary exacerbation will be established by fuchs criteria. exclusion criteria: * patients with allergic bronchopulmonary aspergillosis (abpa) who were treated with systemic steroid therapy and noninvasive mechanical ventilation support will not be included in the study.

Keywords: pulmonary exacerbation
icotinib combined with dihydroaremisinin (dha) therapy in patients with advanced nsclc

Conditions: EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma

Summary: the study was to evaluate the safety, pfs and orr of icotinib/dihydroaremisinin (dha)-based combination therapy in egfr-mutated, advanced nsclc patients who have gradually progressed disease after first-line icotinib treatment.


Eligibility criteria:
inclusion criteria: 1. patients confirmed with stage iv lung adenocarcinoma by pathologic histology or cytology who can't accept surgery and radiotherapy 2. male or female patients aged ≥18 years, life expectancy ≥ 12 weeks 3. eastern cooperative oncology group (ecog) performance status 0-2 4. sensitive egfr gene mutation(19/21) 5. failed with first-line icotinib and have gradually progressed disease more than 6-month duration of first-line icotinib (from the first dosing to the imaging-confirmed progression; and discontinuation of icotinib is less than 14 days) no significantly increased tumor size compared with the final imaging evaluation exclusion criteria: 1. any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease) 2. female subjects should not be pregnant or breast-feeding 3. patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol 4. previous systemic anti-tumor therapy except for icotinib , including chemotherapy or targeted therapy ( including but not limited to monoclonal or antibodies, small molecule tyrosine kinase inhibitor, etc) 5. tumor metastasis of the spinal cord, meninges or meningeal neoplasms confirmed by imaging or cerebrospinal fluid examination
an international randomized trial of additional treatments for covid-19 in hospitalized patients who are all receiving the local standard of care - who-solidarity-germany

Conditions: SARS-CoV-2 Infection; COVID-19; Moderate and Severe COVID-19

Summary: this study is an adaptive, randomized, open-label, controlled clinical trial, performed worldwide in collaboration with who and inserm.


Eligibility criteria:
inclusion criteria: * patients 18 years and older * current sars-cov-2 infection * admitted to the hospital ward or the icu due to covid-19 * spo2 \<= 94% on room air or oxygen demand or breathing support * written informed consent obtained exclusion criteria: * patient's non-consent or inability to informed consent * pregnant or breastfeeding women. * subjects pretreated with one of the study drugs in the past 29 days * anticipated transfer within 72 hours to a non-study hospital * severe co-morbidity with life expectancy \< 3 months * ast or alt \> 5 times the upper limit of normal * stage 4 severe chronic kidney disease or requiring dialysis * contraindications and known intolerance to any of the study drugs * subjects participating in a potentially confounding drug or device trial * any reason why the patient should not participate (investigator's opinion)
effect of l-citrulline supplementation on arginase activity and vascular function in diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: arginase has recently been implicated in an array of vascular conditions including atherosclerosis , hypertension and vascular complication of diabetes. in this study we will determine of l-citrulline; a natural amino acid that is known to have inhibitory effects on arginase activity, on vascular function in type 2 diabetic patients.

vascular dysfunction is a major cause of morbidity and mortality in diabetic patients. the pathological process is characterized by impaired endothelial cell production of the vasodilator and antiplatelet adhesion factor nitric oxide (no) and/or decreased no bioavailability. no is a major regulator of vascular tone and integrity. in endothelial cells, no is produced by activity of endothelial no synthase (enos) on its substrate l-arginine. reduced availability of l-arginine to enos has been implicated in vascular dysfunction in diabetes and a variety of other disease conditions. arginase, which metabolizes l-arginine to urea and ornithine, competes directly with nos for l-arginine. hence increases in arginase activity can decrease tissue and cellular arginine levels, reducing its availability to enos and decreasing no production. during diabetes, elevated levels of arginase can compete with nos for available arginine thus reducing vascular no. we have recently shown that arginase activity is elevated in diabetes. in this proposal we implement a method of flow mediate dilation (fmd) to assess vascular function in diabetic patients. we will study the relation of our vascular function findings with arginase activity levels. we propose that arginase activity measurements could be novel marker of vascular dysfunction in diabetes. the effect of the natural amino acid supplements (l-citrulline) on levels of arginase activity in diabetic patients and vascular function will also be studied.

Eligibility criteria:
inclusion criteria: type 2 diabetes diabetic state: hba1c\>6 exclusion criteria: -

Keywords: vascular dysfunction, l-citrulline, arginase
acetyl-l-carnitine supplementation during hcv therapy with pegylated interferon-α2b plus ribavirin

Conditions: Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis; Fatigue in Workers With Chronic C Hepatitis; Fatigue

Summary: to assess the effects of acetyl-l-carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis c treated with pegylated-interferon-α2b and ribavirin.


Eligibility criteria:
inclusion criteria: * workers who were 18 years of age or older * workers who were infected by hcv and had a quantifiable serum hcv rna level (as determined by polimerase chain reaction, cobas ampliprep/cobas taqman - roche) * cirrhotic workers with a child-pugh score less than 7 exclusion criteria: * workers who had other liver diseases * cancer * severe jaundice * pulmonary and renal chronic diseases, * prostatic diseases * autoimmune diseases * diabetes mellitus * decompensated cirrhosis * pregnancy * cardiopathy * hemoglobinopathies * hemocromatosis * major depression * severe psychiatric pathological conditions
synthetic vs natural estrogen in combined oral contraception

Conditions: Contraception

Summary: the main objective of the study is to compare the metabolic effects of natural estradiol and synthetic ethinylestradiol used in combined oral contraception in healthy women. a progestin-only preparation will be used in comparison. the main goal is to study the effects on glucose metabolism, coagulation and a markers of chronic inflammation (such as hs-crp). our hypothesis is that the natural estradiol preparation will influence blood glucose levels, markers of coagulation and chronic inflammation less than the ethinylestradiol preparation. the progestin-only preparation will not effect these parameters.


Eligibility criteria:
inclusion criteria: * bmi 19-24.9, regular menstrual cycles (21-35 days), a minimum of 2 months without any hormonal contraceptives, no contraindications for use of hormonal contraception exclusion criteria: * polycystic ovaries, hypertension, smoking, alcohol abuse, pregnancy, lactation, abnormal result in pre-screening 2h oral glucose tolerance test, regular medications

Keywords: contraception, oral ethinyl estradiol estradiol valerate dienogest insulin resistance chronic inflammation coagulation
efficacy and safety of dtg/3tc in treatment-naïve hiv-1 infected patients

Conditions: HIV

Summary: non-interventional, retrospective, single arm study of individuals who have initiated a dtg/3tc regimen. medical chart will be reviewed by the investigators. naive subjects will be identified by the clinic database as having initiated dtg/3tc.


Eligibility criteria:
inclusion criteria: * hiv-1 diagnosis * prescribed dtg/3tc alone to manage hiv-1 infection as initial antiretroviral treatment at the study centers exclusion criteria: * hiv-2 diagnosis * previous antiretroviral treatment